Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ADMA BIOLOGICS, INC. entered into Underwriting Agreement with Raymond James & Associates, Inc., acting as representative of the several underwriters named therein valued at approximately $60 million (effective 2022-12-07).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Raymond James & Associates, Inc., acting as representative of the several underwriters named therein
- Value
- approximately $60 million
- Effective
- 2022-12-07
Exact text from the filing
On December 7, 2022, ADMA Biologics, Inc., a Delaware corporation (the “Company”) priced its previously announced underwritten public offering pursuant to which the Company has agreed to issue and sell an aggregate of 20,979,020 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $2.86 per share, for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with the offering (the “Offering”). Pursuant to the terms of the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between the Company and Raymond James & Associates, Inc., acting as representative of the several underwriters named therein (the “Underwriters”)
View on SEC.gov